The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Design, Synthesis, and Evaluations of Substituted 3-[(3- or 4-Carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as Inhibitors of VEGF, FGF, and PDGF Receptor Tyrosine Kinases
Open accessAbstract
Receptor tyrosine kinases (RTKs) have been implicated as therapeutic targets for the treatment of human diseases including cancers, inflammatory diseases, cardiovascular diseases including arterial restenosis, and fibrotic diseases of the lung, liver, and kidney. Three classes of 3-substituted indolin-2-ones containing propionic acid functionality attached to the pyrrole ring at the C-3 position of the core have been identified as catalytic inhibitors of the vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), and platelet-derived growth factor (PDGF) RTKs. Some of the compounds were found to inhibit the tyrosine kinase activity associated with isolated vascular endothelial growth factor receptor 2 (VEGF-R2) [fetal liver tyrosine kinase 1 (Flk-1)/kinase insert domain-containing receptor (KDR)], fibroblast growth factor receptor (FGF-R), and platelet-derived growth factor receptor (PDGF-R) tyrosine kinase with IC(50) values at nanomolar level. Thus, compound 1 showed inhibition against VEGF-R2 (Flk-1/KDR) and FGF-R1 tyrosine kinase activity with IC(50) values of 20 and 30 nM, respectively, while compound 16f inhibited the PDGF-R tyrosine kinase activity with IC(50) value of 10 nM. Structural models and structure-activity relationship analysis of these compounds for the target receptors are discussed. The cellular activities of these compounds were profiled using cellular proliferation assays as measured by bromodeoxyuridine (BrdU) incorporation. Specific and potent inhibition of cell growth was observed for some of these compounds. These data provide evidence that these compounds can be used to inhibit the function of these target receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenes and signal transduction
Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Graziani, A., Kapeller, R., & Soltoff, S. (1991) · Cell · doi:10.1016/0092-8674(91)90639-g · Cited by 2,694
Mohammadi, M., McMahon, G., Sun, L., Tang, C., Hirth, P., Yeh, B. K., Hubbard, S. R., & Schlessinger, J. (1997) · Science · doi:10.1126/science.276.5314.955 · Cited by 1,097
Self-citation[3] Protein kinase phosphorylation site sequences and consensus specificity motifs: Tabulations
Pearson, R. B., & Kemp, B. E. (1991) · Methods in Enzymology · doi:10.1016/0076-6879(91)00127-i · Cited by 1,035
Kinetics of Response in Lymphoid Tissues to Antiretroviral Therapy of HIV-1 Infection
Cavert, W., Notermans, D. W., Staskus, K., Wietgrefe, S. W., Zupancic, M., Gebhard, K., Henry, K., Zhang, Z.-Q., Mills, R., McDade, H., et al. (1997) · Science · doi:10.1126/science.276.5314.960 · Cited by 622
Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain
Mohammadi, M. (1998) · The EMBO Journal · doi:10.1093/emboj/17.20.5896 · Cited by 482
Receptor tyrosine kinases as targets for inhibition of angiogenesis
Shawver, L. K., Lipson, K. E., Fong, T. A. T., McMahon, G., Plowman, G. D., & Strawn, L. M. (1997) · Drug Discovery Today · doi:10.1016/s1359-6446(96)10053-2 · Cited by 79
Self-citation
Cited by
The selectivity of protein kinase inhibitors: a further update
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., Mclauchlan, H., Klevernic, I., Arthur, J. S. C., Alessi, D. R., & Cohen, P. (2007) · Biochemical Journal · doi:10.1042/bj20070797 · Cited by 2,520
Benchmarking sets for molecular docking.
Huang, N., Shoichet, B. K., & Irwin, J. J. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0608356 · Cited by 1,318
VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism
Gerber, H.-P., Malik, A. K., Solar, G. P., Sherman, D., Liang, X. H., Meng, G., Hong, K., Marsters, J. C., & Ferrara, N. (2002) · Nature · doi:10.1038/nature00821 · Cited by 706
SU6656, a Selective Src Family Kinase Inhibitor, Used To Probe Growth Factor Signaling
Blake, R. A., Broome, M. A., Liu, X., Wu, J., Gishizky, M., Sun, L., & Courtneidge, S. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.9018-9027.2000 · Cited by 584
Self-citationGuagnano, V., Furet, P., Spanka, C., Bordas, V., Le Douget, M., Stamm, C., Brueggen, J., Jensen, M. R., Schnell, C., Schmid, H., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006222 · Cited by 477
Roles for Fgf Signaling during Zebrafish Fin Regeneration
Poss, K. D., Shen, J., Nechiporuk, A., McMahon, G., Thisse, B., Thisse, C., & Keating, M. T. (2000) · Developmental Biology · doi:10.1006/dbio.2000.9722 · Cited by 331
Self-citationKim, D. W., Jo, Y. S., Jung, H. S., Chung, H. K., Song, J. H., Park, K. C., Park, S. H., Hwang, J. H., Rha, S. Y., Kweon, G. R., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2845 · Cited by 279
Qi, Y., Zhang, X.-J., Renier, N., Wu, Z., Atkin, T., Sun, Z., Ozair, M. Z., Tchieu, J., Zimmer, B., Fattahi, F., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3777 · Cited by 248
Antidepressant Effects of Fibroblast Growth Factor-2 in Behavioral and Cellular Models of Depression
Elsayed, M., Banasr, M., Duric, V., Fournier, N. M., Licznerski, P., & Duman, R. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.003 · Cited by 169
Lagarde, N., Zagury, J.-F., & Montes, M. (2015) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.5b00090 · Cited by 85
Lüdtke, T. H., Rudat, C., Wojahn, I., Weiss, A.-C., Kleppa, M.-J., Kurz, J., Farin, H. F., Moon, A., Christoffels, V. M., & Kispert, A. (2016) · Developmental Cell · doi:10.1016/j.devcel.2016.08.007 · Cited by 69
Metadata
- Authors
- Sun, L., Tran, N., Liang, C., Tang, F., Rice, A., Schreck, R., Waltz, K., Shawver, L. K., McMahon, G., & Tang, C.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1999-11-19
- Volume
- 42
- Issue
- 25
- Pages
- 5120-5130
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2084612167
- Cited by
- 259
- References
- 6
- FWCI
- 8.60
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.